AstraZeneca 's (NASDAQ: AZN) release of efficacy results for its COVID-19 vaccine turned into something of a soap opera. The company received a rare criticism from the National Institutes of Health (NIH) after first announcing its interim results. In this Motley Fool Live video recorded on March 24, 2021 , Motley Fool contributors Keith Speights and Brian Orelli talk about how AstraZeneca flubbed its better-than-expected COVID vaccine update. (Note: AstraZeneca subsequently released updated efficacy results on March 25 after this video was recorded.)
For further details see:
How AstraZeneca Flubbed Its Better-Than-Expected COVID Vaccine Update